London Daily

Focus on the big picture.
Friday, Aug 22, 2025

Hong Kong Covid-19 panel backs Pfizer vaccine, seeks more Norway deaths details

Hong Kong Covid-19 panel backs Pfizer vaccine, seeks more Norway deaths details

Unanimous backing from experts will go before health secretary for final decision, paving way for mass inoculation drive from mid-February.

A government advisory panel has recommended the approval of the Pfizer-BioNTech Covid-19 vaccine for emergency use in Hong Kong, although it said a “circuit-breaking” mechanism could stop a mass inoculation campaign from being rolled out amid heightened concerns over serious side effects from the jab.

The panel of experts meeting on Monday took three hours to give their unanimous backing to the vaccine developed by the American pharmaceutical giant Pfizer and German company BioNTech, paving the way for the jabs scheme after Lunar New Year. The recommendation will now go before the health secretary for a final decision.

The 12-member Advisory Panel on Covid-19 Vaccines pored over thousands of pages of trial data and other material to offer their verdict on the efficacy and safety of the jab.

Its convenor, Professor Wallace Lau Chak-sing, said the panel decided to recommend use of the vaccine after concluding the benefits outweighed the risks, considering all the information provided.

“After discussing it thoroughly at the meeting, all 12 members of the panel have decided to recommend the approval of the use of the vaccine,” Lau told a press conference.

Phase three trials showed the vaccine achieved an efficacy rate of about 95 per cent for recipients over the age of 16, but recent reports of serious side effects had raised concerns.

Lau said the panel would seek more information from Fosun Pharmaceutical – the mainland China partner of BioNTech – and regulatory agencies in Norway, where at least 29 elderly recipients of the jab died.

“According to the information we have got, in Norway, up to 42,000 have actually received the vaccine,” Lau said, adding that of the 29 deaths, “13 have been suggested to be probably related to the vaccine”.

He said the panel still needed more data from Fosun on the causes of death of the 13.

“We understand they were all elderly, they all had multiple different medical conditions,” he said.

“We need to know whether their deaths were actually related to their underlying problems or to the vaccine.”

Citing Pfizer-BioNTech’s data, Lau said on average only 11.1 people per 1 million had a serious allergic reaction. He said more data would also be sought from Germany, where 10 people had died out of 800,000 recipients.

Addressing reports of recipients developing Bell’s palsy, a temporary facial paralysis, Lam said the condition could be treated with steroids.

Panel member Professor David Hui Shu-cheong added the condition usually affected one in every 100,000 people and just one country had reported a higher than normal rate post-inoculation.

Asked why the panel did not wait for extra data on mortality rates overseas, Lau said only that the experts would continue to look into side effects elsewhere.

Lau also did not detail the circumstances under which the panel would recommend the government halt use of the vaccines.

“I think it will be very difficult to say here what are the clear definitions [when we will recommend the Food and Health Bureau stop use of the vaccine],” he said.

“It really depends on the overall benefits of this vaccine to the population of Hong Kong and the possible side effects that we will encounter later on.”

The panel is made up of public health, infectious disease, immunology, drug regulation and clinical care experts.

Lau is a former president of the Hong Kong Academy of Medicine and chair of rheumatology and clinical immunology at the University of Hong Kong.


Hong Kong has also procured Beijing-based Sinovac’s vaccine.


Two infectious disease experts, Dr Leung Chi-chiu and Dr Joseph Tsang Kay-yan, who are not on the panel, agreed with the decision, saying it was needed to get the roll-out moving, as the remaining approval procedures could still take time.

Leung believed that if the panel had failed to reach a decision, Pfizer-BioNTech could have delayed the delivery of the vaccine, as the companies had already held up supplies to some European countries.

He added recent reports did not show significant side effects of the vaccine in younger recipients, so the government could still tweak the inoculation order and protect vulnerable elderly residents if necessary.

A government spokesman welcomed the panel’s recommendation, and said the secretary for food and health would reach her decision as soon as possible.

The Post reported last week that the Pfizer-BioNTech vaccine was the first to apply for an emergency roll-out in Hong Kong, submitting its application in early January.

Hong Kong has reached purchase agreements for three vaccines, procuring 7.5 million doses of each. Aside from the Pfizer-BioNTech jabs, supplied by Fosun Pharma, the city has also procured Beijing-based Sinovac’s vaccine and one jointly developed by British-Swedish pharmaceutical firm AstraZeneca and Oxford University.

The city aims to roll out the inoculation programme after the Lunar New Year holiday in mid-February, with priority given to high-risk groups such as the elderly and health care workers.

Originally, Sinovac’s doses were expected to arrive in the city this month, followed by Pfizer-BioNTech shots in the first quarter and the AstraZeneca vaccine in the middle of the year.

Newsletter

Related Articles

0:00
0:00
Close
Ukraine Declares De Facto War on Hungary and Slovakia with Terror Drone Strikes on Their Gas Lifeline
Animated K-pop Musical ‘KPop Demon Hunters’ Becomes Netflix’s Most-Watched Original Animated Film
New York Appeals Court Voids Nearly $500 Million Civil Fraud Penalty Against Trump While Upholding Fraud Liability
Elon Musk tweeted, “Europe is dying”
Far-Right Activist Convicted of Incitement Changes Gender and Demands: "Send Me to a Women’s Prison" | The Storm in Germany
Hungary Criticizes Ukraine: "Violating Our Sovereignty"
Will this be the first country to return to negative interest rates?
Child-free hotels spark controversy
North Korea is where this 95-year-old wants to die. South Korea won’t let him go. Is this our ally or a human rights enemy?
Hong Kong Launches Regulatory Regime and Trials for HKD-Backed Stablecoins
China rehearses September 3 Victory Day parade as imagery points to ‘loyal wingman’ FH-97 family presence
Trump Called Viktor Orbán: "Why Are You Using the Veto"
Horror in the Skies: Plane Engine Exploded, Passengers Sent Farewell Messages
MSNBC Rebrands as MS NOW Amid Comcast’s Cable Spin-Off
AI in Policing: Draft One Helps Speed Up Reports but Raises Legal and Ethical Concerns
Shame in Norway: Crown Princess’s Son Accused of Four Rapes
Apple Begins Simultaneous iPhone 17 Production in India and China
A Robot to Give Birth: The Chinese Announcement That Shakes the World
Finnish MP Dies by Suicide in Parliament Building
Outrage in the Tennis World After Jannik Sinner’s Withdrawal Storm
William and Kate Are Moving House – and the New Neighbors Were Evicted
Class Action Lawsuit Against Volkswagen: Steering Wheel Switches Cause Accidents
Taylor Swift on the Way to the Super Bowl? All the Clues Stirring Up Fans
Dogfights in the Skies: Airbus on Track to Overtake Boeing and Claim Aviation Supremacy
Tim Cook Promises an AI Revolution at Apple: "One of the Most Significant Technologies of Our Generation"
Apple Expands Social Media Presence in China With RedNote Account Ahead of iPhone 17 Launch
Are AI Data Centres the Infrastructure of the Future or the Next Crisis?
Cambridge Dictionary Adds 'Skibidi,' 'Delulu,' and 'Tradwife' Amid Surge of Online Slang
Bill Barr Testifies No Evidence Implicated Trump in Epstein Case; DOJ Set to Release Records
Zelenskyy Returns to White House Flanked by European Allies as Trump Pressures Land-Swap Deal with Putin
The CEO Who Replaced 80% of Employees for the AI Revolution: "I Would Do It Again"
Emails Worth Billions: How Airlines Generate Huge Profits
Character.ai Bets on Future of AI Companionship
China Ramps Up Tax Crackdown on Overseas Investments
Japanese Office Furniture Maker Expands into Bomb Shelter Market
Intel Shares Surge on Possible U.S. Government Investment
Hurricane Erin Threatens U.S. East Coast with Dangerous Surf
EU Blocks Trade Statement Over Digital Rule Dispute
EU Sends Record Aid as Spain Battles Wildfires
JPMorgan Plans New Canary Wharf Tower
Zelenskyy and his allies say they will press Trump on security guarantees
Beijing is moving into gold and other assets, diversifying away from the dollar
Escalating Clashes in Serbia as Anti-Government Protests Spread Nationwide
The Drought in Britain and the Strange Request from the Government to Delete Old Emails
Category 5 Hurricane in the Caribbean: 'Catastrophic Storm' with Winds of 255 km/h
"No, Thanks": The Mathematical Genius Who Turned Down 1.5 Billion Dollars from Zuckerberg
The surprising hero, the ugly incident, and the criticism despite victory: "Liverpool’s defense exposed in full"
Digital Humans Move Beyond Sci-Fi: From Virtual DJs to AI Customer Agents
YouTube will start using AI to guess your age. If it’s wrong, you’ll have to prove it
Jellyfish Swarm Triggers Shutdown at Gravelines Nuclear Power Station in Northern France
×